Tandem Mass Spectrometry Newborn Screening for Inborn Errors of Intermediary Metabolism: Abnormal Profile Interpretation

Author(s): C. Fernandez-Lainez, JJ. Aguilar-Lemus, M. Vela-Amieva, I. Ibarra-Gonzalez

Journal Name: Current Medicinal Chemistry

Volume 19 , Issue 26 , 2012

Become EABM
Become Reviewer


Expanded newborn screening for inherited metabolic disorders using tandem mass spectrometry was introduced in 1990’s and is widely used around the world. In contrast to conventional screening methods, tandem mass spectrometry does not measure single analytes but identifies and quantifies metabolite profiles; one single blood spot analyzed provides information of about 60 metabolites including amino acids, acylcarnitines and related ratios that enable the diagnosis of approximately 50 different diseases. However, the interpretation of these profiles can become quite complex. The aim of this work is to present in an easy and practical manner a comprehensive compilation of information needed for tandem mass neonatal screening profile interpretation, and basic actions for immediate follow up of abnormal results, including the tests that are required for confirmatory purposes. Other conditions not attributable to metabolic disorders which can lead to an abnormal profile of these markers are also described as well as a series of general recommendations which would be useful for health professionals who are beginning newborn screening for inborn errors of intermediary metabolism using tandem mass spectrometry.

Keywords: Acylcarnitines, amino acids, expanded newborn screening, false negative results, false positive results, inherited metabolic disorders, interpretation of expanded newborn screening, maternal inherited metabolic disorders, abnormal results, tandem mass, markers.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Page: [4511 - 4522]
Pages: 12
DOI: 10.2174/092986712803251539
Price: $65

Article Metrics

PDF: 35